Functionalized graphene oxide for anti-VEGF siRNA delivery: preparation, characterization and evaluation in vitro and in vivo

Ren, Lulu; Zhang, Yifan; Cui, Chunying; Bi, Yanzhao; Ge, Xu

doi:10.1039/c7ra00810d

Cited by 31 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functionalized GO as a nonviral carrier for siRNA delivery has been explored in previous research. 54 The result of gene therapy is remarkable, but it also has some limitations, such as transfection efficiency, instability etc. In this study, modified GO had the ability to complete co-delivery of DOX and VEGF-siRNA into HeLa cells.…”

Section: Resultsmentioning

confidence: 99%

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Sun¹,

Wang²,

Cui³

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

BackgroundGraphene oxide (GO) has attracted intensive interest in biological and medical fields in recent years due to its unique physical, chemical, and biological properties. In our previous work, we proved that GO could deliver small interfering RNA (siRNA) into cells and downregulate the expression of the desired gene.MethodsThis study investigated the potential of a modified GO nanocarrier for co-delivery of siRNA and doxorubicin (DOX) for enhanced cancer therapy. Fourier transform infrared spectroscopy, laser particle size analyzer, UV-visible spectroscopy, gel electrophoresis retardation, and in vitro release assay were studied.ResultsThe results of real-time polymerase chain reaction revealed that the expression of vascular endothelial growth factor (VEGF) mRNA was decreased 46.84%±3.72% (mean ± SD). Enzyme-linked immunosorbent assay indicated that the expression of VEGF protein was down-regulated to 52.86%±1.10% (mean ± SD) in vitro. In vivo tumor growth assay GO-poly-l-lysine hydrobromide/folic acid (GPF)/DOX/siRNA exhibited gene silencing and tumor inhibition (66.95%±2.35%, mean ± SD) compared with naked siRNA (1.62%±1.47%, mean ± SD) and DOX (33.63%±5.85%, mean ± SD). GPF/DOX/siRNA exhibited no testable cytotoxicity.ConclusionThe results indicated that co-delivery of siRNA and DOX by GPF could be a promising application in tumor clinical therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Sun¹,

Wang²,

Cui³

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

“…The abilities for chemical modification in combination with its low cytotoxicity [116] provide GO broad opportunities for biological and medical applications. Late publications report using chemically modified GO as drag carrier for cancer therapy [117] and tool for gene cancer therapy based on ribonucleic acid (RNA) interference [118]. The combination of GO with quantum dots of AgInZnS produces tunable photoluminescence and can be used for in vivo optical imaging of cancer cells and for phototheraphy [119].…”

Section: Medicine and Biologymentioning

confidence: 99%

Graphene Oxide and Derivatives: The Place in Graphene Family

2019

View full text Add to dashboard Cite

Graphene oxide (GO) is useful and promising material for graphene based applications in electronic, optics, chemistry, energy storage, and biology. At the beginning of graphene history GO was only a simple and cheap step for preparation of single and multilayer graphene films and bulk structures by reduction. The further studies revealed the substantial structure imperfection of graphene oxide derived materials due to the defects in initial graphite and incompletion of reducing process. However, the results of recent research demonstrated a great amount of unique chemical, optical and electronic properties of graphene oxide that allow regarding it as independent nanomaterial possessing a large area of applications. In general, it represents the ultra-large organic molecule containing 2D carbon mesh. Unlike conventional graphene it provides wide range of chemical methods for attachment of various functional groups to its surface for control optical transparency, electrical and thermal conductance. Recently developed methods for preparation of graphene oxide derivatives saturated by carboxyl groups open the new attractive application areas in green technologies including energy storage and utilizing nuclear wastes. The goal of the review is to summarize the results of recent studies of graphene oxide, derivatives and reveal the most promising directions to focus the efforts of researchers.

show abstract

“…This GO-PLL-SDGR/siRNA complex could deliver VEGF-siRNA into tumor cells and down-regulate the expression of VEGF effectively to inhibit the tumor growth in a S180 xenograft tumor model. 250 These results indicated that targeting cationic GO /siRNA delivery system has great application potential in cancer therapy. Moreover, a GO based siRNA/drug co-delivery system was developed by Zhang et al , which concluded a PEI-grafted GO nanocarrier for delivery of Bcl-2 siRNA and doxorubicin.…”

Section: Non-metallic Core Hybrid With Organic Shell Delivery Systemmentioning

confidence: 92%

Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics

et al. 2018

View full text Add to dashboard Cite

Cancer treatment still faces a lot of obstacles such as tumor heterogeneity, drug resistance and systemic toxicities. Beyond the traditional treatment modalities, exploitation of RNA interference (RNAi) as an emerging approach has immense potential for the treatment of various gene-caused diseases including cancer. The last decade has witnessed enormous research and achievements focused on RNAi biotechnology. However, delivery of small interference RNA (siRNA) remains a key challenge in the development of clinical RNAi therapeutics. Indeed, functional nanomaterials play an important role in siRNA delivery, which could overcome a wide range of sequential physiological and biological obstacles. Nanomaterial-formulated siRNA systems have potential applications in protection of siRNA from degradation, improving the accumulation in the target tissues, enhancing the siRNA therapy and reducing the side effects. In this review, we explore and summarize the role of functional inorganic-organic hybrid systems involved in the siRNA therapeutic advancements. Additionally, we gather the surface engineering strategies of hybrid systems to optimize for siRNA delivery. Major progress in the field of inorganic-organic hybrid platforms including metallic/non-metallic cores modified with organic shells or further fabrication as the vectors for siRNA delivery is discussed to give credit to the interdisciplinary cooperation between chemistry, pharmacy, biology and medicine.

show abstract

Functionalized graphene oxide for anti-VEGF siRNA delivery: preparation, characterization and evaluation in vitro and in vivo

Abstract: GO–PLL–SDGR/VEGF-siRNA inhibits tumor growth as a tumor targeting delivery system.

Cited by 31 publications

References 56 publications

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo

Graphene Oxide and Derivatives: The Place in Graphene Family

Engineering functional inorganic–organic hybrid systems: advances in siRNA therapeutics

Contact Info

Product

Resources

About